Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by H. Abken
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
Cancer Research
Cancer Research
Oncology
Related publications
CML Hematopoietic Stem Cells Expressing IL-1RAP Can Be Targeted by Chimeric Antigen Receptor (CAR)-engineered T Cells
Cancer Research
Cancer Research
Oncology
Genetically Engineered T Cells Expressing a HER2-specific Chimeric Receptor Mediate Antigen-Specific Tumor Regression
Cancer Gene Therapy
Cancer Research
Molecular Medicine
Molecular Biology
Chimeric Antigen Receptor T-Cells
Cancer Journal
Cancer Research
Oncology
High-Throughput Screening of Human Tumor-Antigen Specific CD4 T Cells, Including Neo-Antigen Reactive T Cells
Clinical Cancer Research
Cancer Research
Oncology
Impaired Tumor Antigen Processing by Immunoproteasome-Expressing CD40-activated B Cells and Dendritic Cells
Cancer Immunology, Immunotherapy
Cancer Research
Medicine
Oncology
Allergy
Immunology
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
Frontiers in Immunology
Allergy
Immunology
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins
Amelioration of Colitis by Genetically Engineered Murine Regulatory T Cells Redirected by Antigen-Specific Chimeric Receptor
Gastroenterology
Hepatology
Gastroenterology
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin's Lymphoma: An Open-Label Phase 1 Trial
The Lancet
Medicine
